Last reviewed · How we verify

Pembrolizumab/Quavonlimab — Competitive Intelligence Brief

Pembrolizumab/Quavonlimab (Pembrolizumab/Quavonlimab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/TIGIT inhibitor. Area: Oncology.

phase 3 PD-1/TIGIT inhibitor PD-1, TIGIT Oncology Biologic Live · refreshed every 30 min

Target snapshot

Pembrolizumab/Quavonlimab (Pembrolizumab/Quavonlimab) — Merck Sharp & Dohme LLC. Pembrolizumab/Quavonlimab is a combination of a PD-1 inhibitor and a TIGIT inhibitor, which works by blocking the PD-1 and TIGIT proteins to enhance the body's immune response against cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pembrolizumab/Quavonlimab TARGET Pembrolizumab/Quavonlimab Merck Sharp & Dohme LLC phase 3 PD-1/TIGIT inhibitor PD-1, TIGIT

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/TIGIT inhibitor class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pembrolizumab/Quavonlimab — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-quavonlimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: